Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study

Autor:	Joseph R. Calabrese, Wayne Macfadden, Jose Manuel Goikolea, Eduard Vieta, Shane Raines
Rok vydání:	2007
Předmět:	Adult Male medicine.medical_specialty Dibenzothiazepines Bipolar Disorder Placebo-controlled study Placebo Quetiapine Fumarate Double-Blind Method Internal medicine medicine Secondary Prevention Humans Bipolar disorder Psychiatry Biological Psychiatry Psychiatric Status Rating Scales Dose-Response Relationship Drug Hamilton Rating Scale for Depression Middle Aged medicine.disease Psychiatry and Mental health Treatment Outcome Clinical Global Impression Quetiapine Female medicine.symptom Psychology Mania medicine.drug Antipsychotic Agents
Zdroj:	Bipolar disorders. 9(4)
ISSN:	1398-5647
Popis:	Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W for the BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Objectives: To investigate the efficacy and tolerability of quetiapine monotherapy in patients with bipolar I or II disorder with a rapid-cycling disease course. Methods: Adult patients with a DSM-IV diagnosis of bipolar disorder, most recent episode depressed, with a rapid-cycling disease course from a previously completed multicenter trial randomized to 8 weeks of treatment with quetiapine 600 mg/day (n = 31), quetiapine 300 mg/day (n = 42), or placebo (n = 35) were included in this sub-analysis. The primary efficacy variable was change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. Results: Quetiapine (600 and 300 mg/day) provided significantly greater mean reductions from baseline to week 8 in the MADRS total score than placebo (-21.1, -20.7 versus -11.6, both p < 0.001) in this patient population. Effect sizes in patients with a rapid-cycling disease course were 1.2 (600 mg/day) and 1.1 (300 mg/day) and were similar for bipolar I (0.98 and 1.22) and bipolar II (1.45 and 0.97) sub-groups. Significant improvements were also noted on the Clinical Global Impression, Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire scales. Quetiapine was generally well tolerated with moderate increases in weight and extrapyramidal side effects compared to placebo. The incidence of treatment-emergent mania was similar to placebo. Conclusions: Quetiapine monotherapy (600 or 300 mg/day) is clinically effective and well tolerated in the short-term treatment of depressive episodes in patients with bipolar I or II disorder who have a rapid-cycling disease course.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a823f25b7d55607d849c99efab7a4ad https://pubmed.ncbi.nlm.nih.gov/17547587 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.